News
SPRC
6.61
-4.62%
-0.32
Weekly Report: what happened at SPRC last week (0803-0807)?
Weekly Report · 19h ago
SciSparc's NeuroThera Labs Initiates Phase IIb Clinical Study To Evaluate SCI-110 Drug Candidate To Treat Tourette Syndrome
Benzinga · 5d ago
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
Barchart · 5d ago
Weekly Report: what happened at SPRC last week (0727-0731)?
Weekly Report · 08/03 09:59
What's Going On With SciSparc Shares On Friday?
Benzinga · 07/31 14:22
SciSparc Subsidiary NeuroThera Hits Quantum Milestone in Clinical Data Analytics
TipRanks · 07/31 13:47
Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up
NASDAQ · 07/30 03:40
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 07/29 21:06
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 07/29 17:06
Scisparc Ltd trading resumes
TipRanks · 07/29 14:00
Scisparc Ltd trading halted, volatility trading pause
TipRanks · 07/29 13:56
SciSparc Moves Into Agentic AI With New Scientific Advisory Board
TipRanks · 07/29 13:30
SciSparc's NeuroThera Labs Subsidiary Completes Internal Validation Of Quantum Sampling Workflow Developed Platform For Clinical Trials Data Analysis
Benzinga · 07/29 12:36
SciSparc to target agentic artificial intelligence market
TipRanks · 07/27 13:16
Weekly Report: what happened at SPRC last week (0720-0724)?
Weekly Report · 07/27 10:03
Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus
NASDAQ · 07/24 02:45
Weekly Report: what happened at SPRC last week (0713-0717)?
Weekly Report · 07/20 10:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 07/15 21:05
SciSparc initiates SCI-110 clinical trial in Germany
TipRanks · 07/15 13:06
SciSparc’s subsidiary NeuroThera Labs Initiates Phase IIb Clinical Trial Site At Hannover Medical School In Germany For SCI-110, Proprietary Cannabinoid-Based Treatment Candidate For Tourette Syndrome In Adults
Benzinga · 07/15 13:00
More
Webull provides a variety of real-time SPRC stock news. You can receive the latest news about Scisparc through multiple platforms. This information may help you make smarter investment decisions.
About SPRC
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.